COMPANY

EydisBio

HQ: Durham, NC source · eydisbio.com ↗ · Southeast

EydisBio is currently developing a series of highly selective protein kinase inhibitors. From company website Source · Oct 13, 2026

Keywords: inhibitors kinase

Location: Durham, NC · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $406K (SBIR Phase I 1R43CA310084-01, new, notice Sep 16, 2026). NIH RePORTER 1R43CA310084-01 (Sep 16, 2026)
Evidence (1 event)
- Sep 16, 2026 · NIH RePORTER 1R43CA310084-01
  Organization: EYDIS BIO, INC.; City/State: DURHAM, NC; Project number: 1R43CA310084-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 406496; Administering IC: National Cancer Institute; Project title: Development of a novel, orally bioavailable, TAK1 inhibitor for the treatment of chemotherapy-induced peripheral neuropathy; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Sep 16, 2026 Grant Government grant — SBIR: $406,496 (annual award, as published), announced Sep 16, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 29, 2025 Grant Government grant — NIH N43: $499,825 (annual award, as published), announced Sep 29, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 16, 2025 Grant Government grant — SBIR: $1.42M (annual award, as published), announced Jul 16, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗

Last 2 years.

Sep 16, 2026 Government grant — SBIR: $406,496 (annual award, as published), announced Sep 16, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 29, 2025 Government grant — NIH N43: $499,825 (annual award, as published), announced Sep 29, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 16, 2025 Government grant — SBIR: $1.42M (annual award, as published), announced Jul 16, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗